Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

DOI Full Paper Access

224

Citations

20

References

2023

Year

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, Charles E. Alpers, Stewart Bieler, Dong-Wan Chae, Ulysses Diva, Jürgen Floege, Loreto Gesualdo, Jula K. Inrig,

Abstract

Travere Therapeutics.

References

	Year	Citations
A New Equation to Estimate Glomerular Filtration Rate Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid, Annals of Internal Medicine	2009	25K
Dapagliflozin in Patients with Chronic Kidney Disease Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, New England Journal of Medicine	2020	4.8K
Multiple Imputation for Nonresponse in Surveys. Peter Lynn, Donald B. Rubin Journal of the Royal Statistical Society Series D (The Statistician) ReliabilitySurvey (Human Research)EngineeringWeb Survey MethodMultiple Imputation	1988	2.3K
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Kidney International Glomerular DiseaseGlomerulonephritisHemodialysisUrologyRenal Disease	2021	2.2K
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Brad H. Rovin, Y K Onno Teng, Ellen M. Ginzler, The Lancet GlomerulonephritisAutoimmune DiseaseVoclosporin Versus PlaceboSystemic Lupus Erythematosus TreatmentLupus	2021	534
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Kidney International	2021	369
Long-Term Outcomes in IgA Nephropathy David Pitcher, Fiona Braddon, Bruce M. Hendry, Clinical Journal of the American Society of Nephrology	2023	325
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Carlo Manno, Domenica Torres, Michele Rossini, Nephrology Dialysis Transplantation	2009	305
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy Jicheng Lv, Muh Geot Wong, Michelle Hladunewich, JAMA	2022	294
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial Richard Lafayette, Jens Kristensen, Andrew Stone, The Lancet Primary Iga NephropathyGlomerulonephritisRenal FunctionMedicineRandomised Phase 3	2023	234

Page 1